White House credits Trump deregulation for $26 billion in drug savings

Published



President Trump’s deregulatory agenda has reduced spending on pharmaceuticals by $26 billion since his inauguration, White House officials claimed in a new report Thursday.

The document, published by the Council of Economic Advisers, makes the case that government regulations were overly burdensome in getting generic drug applications reviewed for safety and brought to market. They say that having more drugs in the market, especially if they are cheaper generics, can help drive down prices.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.